<?xml version="1.0" encoding="UTF-8"?>
<p>Our analyses were performed on the intention-to-treat cohort as this cohort preserves the benefits of randomization and ensures unbiased results. Similar results are expected for the per-protocol cohort for two reasons: first, more than 95% of the subjects in both studies received 3 doses of the vaccine, and then, the VE in the per-protocol cohort has been shown to be nearly identical to VE among participants who had received one or more injections [
 <xref rid="pone.0207878.ref009" ref-type="bibr">9</xref>,
 <xref rid="pone.0207878.ref010" ref-type="bibr">10</xref>].
</p>
